Difference between revisions of "Dactinomycin (Cosmegen)"

Revision as of 16:44, 1 March 2019

General information

Class/mechanism: Antibiotic oncologic, intercalates between guanine and cytosine DNA base pairs, inhibiting DNA and RNA synthesis.^[1]^[2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

12/10/1964: Initial FDA approval

Also known as

Generic names: AC-DE, actinomycin D
Brand names: Cosmegen, Dacmozen, Lyovac

References

[insert-1] 1.0 ^1.1 Dactinomycin (Cosmegen) package insert

[2] Dactinomycin (Cosmegen) package insert (locally hosted backup)

[3] Dactinomycin (Cosmegen) patient drug information (Chemocare)

[4] Dactinomycin (Cosmegen) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 39: / Line 39: @@
 [[Category:Osteosarcoma medications]]
 [[Category:Soft tissue sarcoma medications]]
-[[Category:Wilms' tumor medications]]
+[[Category:Wilms tumor medications]]
 [[Category:FDA approved in 1964]]
 [[Category:WHO Essential Cancer Medicine]]